Full-Time

Senior Facilities Engineer

Maravai LifeSciences

Maravai LifeSciences

51-200 employees

Offers oligonucleotide synthesis and immunohistochemistry

Compensation Overview

$100k - $120k/yr

+ Bonus + Equity Grants

San Diego, CA, USA

In Person

Category
Facilities Operations (2)
,
Required Skills
ISO 9001
Requirements
  • Bachelor’s degree in Engineering, Facilities Engineering, Mechanical Engineering, or related technical discipline with 5 years of experience in facilities engineering within a regulated laboratory or manufacturing environment. Equivalent experience considered.
  • Working knowledge of GMP regulations and ISO 9001 and or ISO 13485 standards
  • Experience supporting HVAC, utilities, laboratory infrastructure, and environmental control systems
  • Experience with equipment qualification, validation, and calibration programs
  • Proficiency with CMMS systems and Microsoft Office applications
  • Strong analytical and problem solving skills with ability to conduct root cause investigations
  • Effective communication skills and ability to collaborate cross functionally
Responsibilities
  • Serve as technical owner for facility infrastructure systems including HVAC, electrical distribution, water systems, compressed air, laboratory gases, environmental controls, and waste systems
  • Develop and execute preventive and predictive maintenance programs to improve uptime, asset reliability, and lifecycle management
  • Manage facility and equipment asset records, maintenance schedules, and calibration programs within CMMS systems
  • Lead troubleshooting and root cause investigations for facility related failures and implement sustainable corrective actions
  • Support equipment installation, commissioning, qualification, and validation activities including IQ and OQ where applicable
  • Ensure compliance with GMP, ISO 9001 and or ISO 13485, OSHA, and local and federal regulatory requirements
  • Oversee hazardous material handling, storage, and disposal in partnership with EHS and approved vendors
  • Evaluate and manage external contractors and service providers to ensure cost effectiveness, quality, and timely execution
  • Maintain audit ready documentation including SOPs, maintenance logs, calibration records, and validation documentation
  • Support capital improvement projects, facility expansions, space planning, and business continuity initiatives
  • Perform other functions and duties as required

Maravai LifeSciences provides tools and services for life sciences research and bioproduction, including supplying oligonucleotides for PCR, next-generation sequencing (NGS), and gene editing, as well as immunohistochemistry for cancer research, serving academic institutions, biotechnology firms, and pharmaceutical companies. Oligonucleotide synthesis creates short DNA or RNA strands used in PCR, sequencing, and genome editing workflows; immunohistochemistry uses labeled antibodies to detect proteins in tissue samples. It differentiates itself by combining investment and operational support to incubate and scale life science companies while offering essential research tools. Its goal is to catalyze the development of life science companies to advance human health by providing capital, expertise, and essential research tools.

Company Size

51-200

Company Stage

IPO

Headquarters

San Diego, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • TriLink base revenue grows 15% YoY in Q1 2026 from non-COVID mRNA demand.
  • Molecular Assemblies acquisition in January 2025 enhances enzymatic DNA synthesis.
  • Alphazyme cuts Linea RNAP costs 70% via Applied DNA scale-up in 2024.

What critics are saying

  • Moderna and BioNTech vertically integrate capping by Q4 2026, eliminating TriLink sales.
  • GenScript's CleanScript kits with 20% higher efficiency steal share in Pfizer trials.
  • Thermo Fisher launches integrated mRNA kits in April 2025, eroding CleanCap dominance.

What makes Maravai LifeSciences unique

  • CleanCap® achieves >95% co-transcriptional capping efficiency versus enzymatic methods.
  • CleanCap M6 analog boosts mRNA potency with highest protein expression in 2023.
  • TriLink bundles CleanCap with NTPs, ModTail, and enzymes for streamlined synthesis.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Maravai LifeSciences who can refer or advise you

Benefits

Health Insurance

Company Equity

Fertility Treatment Support

Family Planning Benefits

401(k) Retirement Plan

Paid Vacation

Company News

Valley Times-News
Mar 6th, 2025
MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

MRVI INVESTOR ALERT: Maravai LifeSciences Holdings, Inc. investors with substantial losses have opportunity to lead Class Action lawsuit.

Tidewater News
Mar 1st, 2025
MRVI INVESTIGATION NOTICE: Investigation Launched into Maravai LifeSciences Holdings, Inc. and Attorneys Encourage Investors with Substantial Losses or Witnesses with Relevant Information to Contact Law Firm

SAN DIEGO, March 1, 2025 /PRNewswire/ - The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) focused on whether the company and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors.

Investing.com
Jan 28th, 2025
Maravai LifeSciences expands mRNA manufacturing with new acquisition

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property and assets from Molecular Assemblies, Inc.

LifeCare News
Dec 5th, 2024
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

Maravai LifeSciences appoints R. Andrew Eckert as Chairman of the Board of Directors.

San Diego Business Journal
Nov 25th, 2024
Maravai to Acquire Officinae Bio

More recently, Maravai acquired the molecular biology enzyme provider Alphazyme, LLC, in 2022.